MediWound (NASDAQ:MDWD) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

MediWound (NASDAQ:MDWD) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01), Zacks reports. The company had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $2.59 million. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.

Here are the key takeaways from MediWound’s conference call:

• EscharEx’s VALUE Phase III trial remains on track, with interim sample-size reassessment and enrollment completion targeted by the end of Q1 2027. The company says nearly all of the approximately 40 sites are recruiting.
• MediWound expanded its estimated U.S. peak annual sales opportunity for EscharEx to $1.05 billion after including pressure ulcers, and plans to start a 50-patient diabetic foot ulcer study and a small pressure-ulcer investigator-initiated study in Q4 2026.
• NexoBrid’s U.S. commercial adoption continued to improve, with Vericel reporting record quarterly revenue, hospital unit sales and ordering centers; approximately 80 U.S. burn centers have ordered the product since launch.
• The new master service agreement with Vericel is expected to begin contributing revenue in the second half of 2026, including development programs targeting blast and friction injuries. MediWound reaffirmed 2026 revenue guidance of $24 million–$26 million, weighted heavily toward the second half.
• Financial performance weakened in the first half: Q2 revenue fell to $3.1 million from $5.7 million year over year, while cash and deposits declined to approximately $36 million from $54 million at year-end 2025 after $20 million of first-half cash burn. R&D spending is expected to remain elevated as the VALUE trial advances, and expanded-facility commercial supply is not expected until the second half of 2027.

MediWound Price Performance

MediWound stock traded down $0.07 during midday trading on Friday, reaching $13.46. 17,607 shares of the company traded hands, compared to its average volume of 91,494. MediWound has a 12 month low of $13.40 and a 12 month high of $20.30. The business has a 50 day moving average of $14.36 and a two-hundred day moving average of $15.99. The firm has a market capitalization of $172.90 million, a price-to-earnings ratio of -5.98 and a beta of 0.15.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Finally, Oppenheimer reissued an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, MediWound presently has an average rating of “Hold” and an average price target of $33.00.

Insider Buying and Selling

In related news, Director David Morton Fox bought 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was acquired at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

Several large investors have recently modified their holdings of the company. Quarry LP bought a new position in MediWound in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets boosted its position in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in shares of MediWound during the 4th quarter valued at about $109,000. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.